Melanoma symptoms provide key warning signs that can help you find this disease early, when it is most treatable. Learn ...

Institut Curie researchers have identified a sex-specific molecular pathway connecting E-cadherin loss, estrogen receptor-α ...

Researchers studied the progression-free and overall survival rates of patients with advanced melanoma after cessation of immune checkpoint inhibitor therapy.

The idea that a prolonged interval between diagnosing and treating uveal melanoma can affect prognosis has been at the centre of an active debate.1–5 This issue focuses on a key question for ...

Emergency department (ED) presentations are associated with higher cancer mortality. This study aimed to investigate the ...

Like other cancers, melanoma is rising among young adults. It's now the 2nd most common cancer in 15 to 39 year-olds.

While artificial intelligence (AI) holds promise to improve the diagnosis of melanoma, researchers of a new review outlined ...

American Cancer Society; National Comprehensive Cancer Network Dermatology Nursing. 2005;17 (2):119-131.

Abstract LBA9508 Background: Optimal first line therapy for patients with metastatic melanoma is an immunotherapy regimen containing an anti-PD1 antibody, regardless of tumour BRAF mutation status.

A high-fiber diet may improve response rates and event-free survival outcomes in patients with advanced melanoma receiving standard immunotherapy.

Article Title Comparison of 1 year versus minimum 2 years of anti-PD1-based immunotherapy as first-line treatment for metastatic melanoma: Results of the DANTE phase III trial.